The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar gemcitabine chemotherapy which has bee [...]
For many years ovarian cancer has been referred to as the silent killer due to its vague ignored or misdiagnosed symptoms Because of this and the lack of early-detection tools ovarian cancer often goes undiagnosed until it has reached the later stages whe [...]
The US Food and Drug Administration FDA has approved Keytruda pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 Keytruda is the first Anti- [...]
The five-year survival rate for locally-advanced head and neck cancer is only 46 percent even with treatments including surgery radiation chemotherapy andor genetically targeted treatments such as cetuximab Often the problem is that while treatments initi [...]
Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium for the treatment of patients with high-grade non-muscle invasive bladder cancer NMIBC who have been previously treated with bacillus Calmette-Gurin BCG were released Overall 43 of pa [...]
The US Food and Drug Administration FDA granted Breakthrough Therapy designation for Xalkori crizotinib for the treatment of patients with metastatic non-small cell lung cancer NSCLC with MET exon 14 alterations with disease progression on or after platin [...]
On Saturday Loxo Oncology in a presentation at the American Society of Clinical Oncology annual meeting in Chicago unveiled clinical trial data for LOXO-292 a novel precision cancer medicine targeting tumors containing a mutated protein known as RET About [...]
The US Food and Drug Administration FDA has granted approval to Calquence acalabrutinib for the treatment of patients with mantle cell lymphoma MCL who have received at least one prior therapy Calquence is a highly-selective potent Bruton tyrosine kinase [...]
Northwest Biotherapeutics developer of DCVax personalized immune therapies for solid tumor cancers announced today the publication of interim blinded survival data from itsPhase 3 clinical trial of DCVax-L for newly diagnosed Glioblastoma brain cancerThe [...]
The research team behind an emerging immunotherapy for cancer will present interim findings from an ongoing clinical study in patients with brain cancer at a major research meeting next month Collaborators from organizations including Roswell Park Compreh [...]
